European consensus statement concerning treatment with Zolgensma

13 July 2020

Onasemnogene abeparvovec (Zolgensma) was recently approved by the European Medicine Agency for the treatment of patients with SMA with up to three copies of the SMN2 backup gene or the clinical presentation of SMA type 1.

To facilitate the clinical introduction and use of this gene therapy, a group of prominent European neuromuscular experts have provided eleven consensus statements covering many aspects of treatment with onasemnogene abeparvovec.

Read the statements